ardelyx.com (ARDX) - Year-over-year earnings per share growth for the last twelve months

Ardelyx Pharma - graphic logo of issuer ARDX

Can Ardelyx, Inc. (ARDX) overcome stringent FDA oversight and costly R&D expenditures? The quarterly EPS trend provides the answer, with the 24.70 metric serving as the target level. The success of Ardelyx, Inc. (ARDX) relies on a team of nephrologists united by a mission to save lives. Due to its insulation from macroeconomic factors, the business functions as a defensive asset, ensuring stable income regardless of recessions.

Ardelyx Inc (ARDX) - Earnings per share growth in annualized terms for the last twelve months from 07/04/2022 to 11/15/2026

ARDX (ardelyx.com): analytical breakdowns and indicator data

- share price and expert price forecast:
Stock Price Ardelyx, Inc.|ARDX - Broker Consensus Forecast
- market capitalization indicators:
Market Value Ardelyx Inc|ARDX - Business Value
- book capitalization data:
Book Value per Share Ardelyx|ARDX - Total Stockholders' Equity|Market Cap to Net Assets Ratio ardelyx.com|ARDX - Company Assets
- debt and solvency information:
Total Debt to Capital Ardelyx, Inc.|ARDX - Long-Term Debt to Capital|Short-Term Debt to Equity Ardelyx|ARDX - Aggregate Debt Obligations|Debts to Book Capitalization Ardelyx Inc|ARDX - Company Long-Term Indebtedness|Company Short-Term Debts Ardelyx|Quick Liquidity ardelyx.com
- earnings and valuation multiples indicators:
ARDX - Company Net Income|Future Profit Ardelyx, Inc.|ARDX - Market Cap to Earnings|Projected Price to Earnings Ardelyx|ARDX - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Ardelyx, Inc.|ARDX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Ardelyx|ARDX - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months ardelyx.com|ARDX - Earnings per share growth this year|Earnings growth forecast for next year Ardelyx, Inc.
- sales volume and revenue indicators:
ARDX - Company Sales|Company Future Sales Volume Ardelyx Corp|ARDX - Price-to-Revenue Coefficient|Forward P/S Multiple Ardelyx Corp
Summary company analytics:Ardelyx, Inc. - ARDX
Flagship merchandise of Ardelyx, Inc.

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. This metric allows for an assessment of capital generation efficiency and business scaling rates. By analyzing the quarterly EPS growth rate, an investor separates speculative noise from the fundamental trend. For Ardelyx, Inc. (ARDX), this trend confirms the commercial success of integrating innovative drugs into standards of care. Sustained profit growth here reflects patients' high dependence on the company's unique molecules.

Key competitors

TVTX: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months PROK|Year-over-year earnings per share growth for the last twelve months Akebia Therapeutics, Inc.|Year-over-year earnings per share growth for the last 12 months TVRD (Cara Therapeutics Inc)|Quarterly EPS earnings growth DMAC|UNCY - Earnings per share growth in annualized terms for the last twelve months|rockwellmed.com - Year-over-year net earnings per share growth for the last 12 months|Cadrenal Therapeutics, Inc (CVKD) - Earnings per share growth in annualized terms for the last twelve months|CDT - Year-over-year earnings per share growth for the last twelve months|calliditas.se (CALT) - Year-over-year net earnings per share growth for the last 12 months|RNLX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months ZyVersa Therapeutics (ZVSA)